Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

31 Aug 2013

Abstract excerpt

PURPOSE: Castration-resistant prostate cancer (CRPC) may occur by several mechanisms including the upregulation of androgen receptor (AR), coactivators, and steroidogenic enzymes, including aldo keto reductase 1C3 (AKR1C3). AKR1C3 converts weaker 17-keto androgenic precursors to more potent 17-hydroxy androgens and is consistently the major upregulated gene in CRPC. The studies in the manuscript were undertaken...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldose Reductase and Taurine
Share to Signaling Pathways in Disease

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23995860
DOI: 10.1158/1078-0432.ccr-13-1151

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer GrowthPMID 23995860Read ↗

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity Read ↗

Tissue Distribution of Human AKR1C3 and Rat Homolog in the Adult Genitourinary SystemSemantic proximity Read ↗

Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolismSemantic proximity Read ↗

Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degraderSemantic proximity Read ↗

A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsSemantic proximity Read ↗

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant GrowthSemantic proximity Read ↗

Constitutive activity of the androgen receptor.Semantic proximity Read ↗

Steroid receptor coactivator-3 as a potential molecular target for cancer therapySemantic proximity Read ↗

Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and SurvivalSemantic proximity Read ↗

The long noncoding RNA HORAS 5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional programSemantic proximity Read ↗

Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.Semantic proximity Read ↗

Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.